Kiniksa Pharmaceuticals International, plc (KNSA) FY2026 Q3 P&L / Income Statement

Published Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)

2026-07-01 to 2026-09-30

Revenue by Product and Service by Arrangement

Swipe to see the full flow
Kiniksa Pharmaceuticals International, plc (KNSA) FY2026 Q3 P&L / Income StatementIncome statement for 2026-07-01 through 2026-09-30. View: Product and Service by Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUEOPERATINGPRE-TAXNETUndisclosed (calculated)RevenueIncome from operationsOperating expenses (calculated)Total operating expensesOther income (expense), net (calculated)Income before income taxesNet incomeProvision for income taxesOther income (expense), net (calculated)Other income,net (calculated)$4.82 MIncome before income taxesPretax income$59.06 MRevenueRevenue$285.97 MIncome from operationsIncome from operations$54.24 MNet incomeNet income$47.35 MOperating expenses (calculated)Operating expenses(calculated)$231.73 MProvision for income taxesProvision forincome taxes$11.71 MUndisclosed (calculated)Undisclosed (calculated)$285.97 MTotal operating expensesTotal operating expenses$231.73 M
Chart details

Kiniksa Pharmaceuticals International, plc (KNSA) FY2026 Q3 P&L / Income Statement

Income statement for 2026-07-01 through 2026-09-30. View: Product and Service by Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenue
285,970,000 US dollars
Operating expenses (calculated)
231,734,000 US dollars
Income from operations
54,236,000 US dollars
Other income (expense), net (calculated)
4,821,000 US dollars
Income before income taxes
59,057,000 US dollars
Provision for income taxes
11,712,000 US dollars
Net income
47,345,000 US dollars
License and collaboration revenue - Territory License - ARCALYST
0 US dollars
License and collaboration revenue - Worldwide License - Vixarelimab
0 US dollars
Undisclosed (calculated)
285,970,000 US dollars
Total operating expenses
231,734,000 US dollars

Chart connections

  • Revenue minus operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
Kiniksa Pharmaceuticals International, plc (KNSA) FY2026 Q3 P&L / Income Statement Sankey chart, Product and service — Product and Service by Collaborative Arrangement and Arrangement Other than Collaborative view
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!